stockrow
Friday 6 November 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
Lisata Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170,000.00, down 83.0% from fiscal 2024.
- Revenue
- −98.3%
- EPS
- +40.7%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
1.02
0.03
+3.03%
Follow LSTA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | — | — |
P/S ratio |
— | 1.06 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (4.97) | — | — | |
P/B ratio |
— | 1.11 | — | — | |
Price to Tangible BV |
— | 1.12 | — | — | |
EV/Sales |
— | 0.22 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (0.21) | — | — | |
EV/FCF |
— | (0.21) | — | — | |
Quick Ratio |
4.27 | 5.20 | 3.94 | 3.50 | |
Current Ratio |
4.72 | 5.76 | 4.23 | 3.69 | |
Net Debt/EBITDA |
4.33 | 5.21 | 2.64 | 2.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.58 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 1.10 | 0.69 | 0.90 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,135.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,045.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 225.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.90 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (102.69%) | — | — | |
Free Cash Flow Yield |
— | (98.88%) | — | — | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.37) | (0.34) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.37) | (0.34) | (0.29) | |
Cash per Share |
2.17 | 1.84 | 1.45 | 1.15 | |
Shareholders Equity per Share |
1.96 | 1.68 | 1.19 | 0.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.96 | 1.68 | 1.19 | 0.88 | |
Free Cash Flow |
(3.34) | (3.25) | (3.08) | (2.65) | |
Working Capital |
17.01 | 14.63 | 10.71 | 8.03 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
16.94 | 14.56 | 10.63 | 7.98 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.25 | — | — | — | |
Average Payables |
0.59 | 1.15 | 0.56 | 0.81 | |
Average Assets |
29.98 | 26.37 | 21.52 | 18.09 | |
Average Common Equity |
25.28 | 21.96 | 17.89 | 14.38 |
Columns are period end dates · fundamentals updated 26 Oct 2026